Work

1382P Phase Ib/II open-label, randomised evaluation of second-line atezolizumab (atezo) + linagliptin (lina) vs ramucirumab (ram) + paclitaxel (pac) in MORPHEUS-gastric cancer

Year: 2021

Type: article

Study design: Clinical Trial

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2021.08.1491

Authors: J. Lee, J.A. Ajani, H.C. Chung, Y-K. Kang, S. Iqbal, S. Allen, N. Al-Sakaff, J. Decalf, S. Li, J. Pintoffl, P. Sayyed, Y-J. Bang

Institutions: Samsung Medical Center, Sungkyunkwan University, The University of Texas MD Anderson Cancer Center, Yonsei University, Yonsei University Health System, Yonsei Cancer Hospital, Asan Medical Center, University of Ulsan, University of Southern California, USC Norris Comprehensive Cancer Center, Genentech, F. Hoffmann-La Roche AG, Roche (China), Seoul National University

Language: English

Topic: Gastric Cancer Management and Outcomes

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W3204951143

FWCI: 0.162

Cites:

Cited by: 2

Related to: 10